Opthea Ltd (ASX: OPT) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Opthea Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$738.77 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
1.23 billion
Earnings per share
-0.133
Dividend per share
N/A
Year To Date Return
N/A
Earnings Yield
N/A
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Opthea Ltd (ASX: OPT)
Latest News
Growth Shares
3 quality mid cap ASX shares to buy with $3,000
Share Gainers
These All Ords shares have more than doubled in 12 months
⏸️ ASX Shares
10 top ASX shares to buy for strong long term returns
Growth Shares
Grow your wealth with these quality ASX healthcare shares
Growth Shares
These mid cap ASX shares could be long term market beaters
Share Gainers
Why Afterpay, Challenger, Opthea, & Wesfarmers are surging higher
Coronavirus News
Top broker tips Opthea shares as a strong buy during the coronavirus crisis
Share Market News
Why this ASX healthcare share has risen over 200% in the past year
Share Market News
3 ASX healthcare growth shares to add to your 2020 watchlist
Growth Shares
3 excellent ASX healthcare shares to bring your portfolio to life
⏸️ ASX Shares
Experts are tipping these healthcare shares for big things
Share Market News
Paradigm Biopharmaceuticals shares have skyrocketed. Should you invest?
Frequently Asked Questions
-
No, Opthea does not pay shareholder dividends at this time.
-
Opthea Limited listed on the ASX on 18 April 1991.
OPT ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Opthea Ltd
Opthea Limited (ASX: OPT) is a biopharmaceutical company specialising in the development of biological therapeutics for retinal eye diseases. The company is developing a novel therapy, OPT-302, designed to be used in combination with existing therapies. OPT-302, the company's leading drug candidate, has the potential to address wet age-related macular degeneration (AMD) and diabetic macular edema (DME) in patients. It is currently at Phase 3 clinical trial stage.
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 19 Dec 2025 | Lawrence Gozlan | Issued | 41,000,000 | $24,600,000 |
Directors' share plan. As per annouuncement on 23-12-2025
|
| 19 Dec 2025 | Katherine(Kathy) Connell | Issued | 41,000,000 | $24,600,000 |
Directors' share plan.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Lawrence Bernard Gozlan | Non-Executive Director | Jul 2020 |
Mr Gozlan a biotechnology investor and advisor, and is the Life Sciences Investment Manager at Jagen Pty Ltd, an international private investment organization. He is also the Chief Investment Officer and Founder of Scientia Capital, a specialized global investment fund focused exclusively on life sciences. Scientia was founded to provide expertise and to manage investments, and more. He is also a member of Risk Committee and Chair of Governance Committee.
|
| Dr Jeremy Levin | Non-Executive ChairmanNon-Executive Director | Oct 2020 |
Dr Levin has served as the Chief Executive Officer of Ovid Therapeutics Inc., and since 2014, as Chairperson of the board of directors, of Ovid. From May 2012 to October 2013, He served as the President and Chief Executive Officer of Teva Pharmaceutical Industries Ltd., a publicly held pharmaceutical company. From September 2007 to December 2012, he held several roles at Bristol Myers Squibb Company, a publicly held pharmaceutical company, ultimately serving as the Senior Vice President of Strategy, Alliances and Transactions. He is also a member of Governance Committee.
|
| Ms Katherine(Kathy) Ellen Danielle Connell | Non-Executive Director | Nov 2024 |
Ms Connell is a healthcare and life sciences leader investment and licensing expertise, delivering deals across pharmaceuticals, medtech, vaccines consumer and digital healthcare for some of the companies. For the past 20 years, she has held senior executive leadership positions in biotechnology, pharmaceutical, medical device and consumer health sectors specialising in business development, licensing, acquisitions and venture investment, as well as having worked in healthcare and Life Sciences executive search and management consulting with Korn Ferry. She is member of Risk Committee and Governance Committee.
|
| Mr Hamish George | Chief Financial OfficerJoint Company Secretary | Oct 2025 |
-
|
| Ms Stephanie Vipond | Joint Company Secretary | Oct 2025 |
-
|
| Judith Robertson | Chief Commercial Officer |
-
|
|
| Tom Reilly | Chief Financial Officer |
-
|
|
| Hamish George | Chief Financial OfficerJoint Company Secretary |
-
|
|
| Parisa Zamir | Chief Medical Officer |
-
|
|
| Megan Baldwin | Founder Chief Innovation Officer and Executive Director |
-
|
|
| Stephanie Vipond | Joint Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| HSBC Custody Nominees (Australia) Limited | 194,136,944 | 15.77% |
| Citicorp Nominees Pty Limited | 183,915,116 | 14.94% |
| Ubs Nominees Pty Ltd | 166,500,018 | 13.52% |
| Jp Morgan Nominees Australia Pty Limited | 138,447,073 | 11.24% |
| BNP Paribas Noms Pty Ltd | 53,851,264 | 4.37% |
| HSBC Custody Nominees(Australia) Limited Gsco Eda | 47,047,963 | 3.82% |
| HSBC Custody Nominees (Australis) Limited A/C2 | 44,858,465 | 3.64% |
| Warbont Nominees Pty Ltd <Unpaid Entrepot A/C> | 40,072,530 | 3.25% |
| Merrill Lynch(Australia) Nominees Pty Limited | 35,396,820 | 2.87% |
| BNP Paribas Nominees Pty Ltd <Ib Au Noms Retailclient> | 19,689,961 | 1.60% |
| Information Logistics Pty Ltd <Information Logistics A/C> | 18,076,530 | 1.47% |
| National Nominees Limited | 16,523,839 | 1.34% |
| HSBC Custody Nominees (Australia) Limited <Nt Comnwlth Super Corp A/C> | 10,336,919 | 0.84% |
| Jadeglen Investments Pty Ltd <David Thurin Family A/C> | 9,004,711 | 0.73% |
| Safo Investments Pty Ltd <Safo Investment A/C> | 8,134,875 | 0.66% |
| M & S Skyleisure Pty Ltd, M & S Skyleisure No 2 A/C> | 6,581,336 | 0.53% |
| M & S Skyleisure Pty Ltd, M & S Skyleisure No 1 A/C> | 6,581,335 | 0.53% |
| BNP Paribas Noms (Nz) Ltd | 6,410,388 | 0.52% |
| Armada Trading Pty Limited | 5,005,806 | 0.43% |
| Jadeglen Investments Pty Ltd <David Thurin Family A/C> i | 5,000,000 | 0.41% |
